Spruce Biosciences Inc (US:SPRB) — Company Overview, News & Financial Data
Spruce Biosciences develops novel therapies for rare endocrine disorders, focusing on innovative treatments for patients.

About Spruce Biosciences Inc
Spruce Biosciences (NASDAQ:SPRB) focuses on developing novel therapies for rare endocrine disorders. The company is dedicated to advancing treatments that can significantly improve the lives of patients suffering from these conditions. Their primary project centers around tildacerfont, a promising drug candidate aimed at addressing congenital adrenal hyperplasia, a rare disorder impacting the adrenal glands. Spruce Biosciences is committed to pushing the boundaries of medical research to provide new hope for patients with limited treatment options, ultimately aiming to become a beacon of innovation in the rare disease therapeutic space.
Snapshot
Operations
Products and/or services of Spruce Biosciences Inc
- Development of tildacerfont, a CRF1 receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH).
- Exploration of tildacerfont's potential in treating polycystic ovary syndrome (PCOS).
- Investigation into applications of tildacerfont for patients with Cushing's disease.
- Advanced clinical trials for assessing safety and efficacy of tildacerfont in diverse patient populations.
- Collaborative research initiatives to discover new therapeutic targets within the endocrinology field.
- Partnership programs to enhance drug development and commercialization efficiency.
Spruce Biosciences Inc executive team
- Mr. Michael G. GreyExecutive Chairman
- Dr. Javier Szwarcberg M.D., M.P.H.CEO & Director
- Mr. Samir M. Gharib CPA, M.B.A.President & CFO
- Dr. Kirk Ways M.D., Ph.D.Chief Medical Officer & Director